Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relaps
Immix Biopharma reported an 89% complete-response rate in an interim update covering all NEXICART-2 patients. The MRD-negative results create a near-term clinical catalyst around whether the therapy can sustain its potential efficacy in relapsed disease.
Immix Biopharma said 21 of 25 new patients in the NEXICART-2 study were in complete response at the interim update, while the remaining four were MRD-negative. That means all 25 patients were either in complete response or MRD-negative, according to the company’s announcement.
The reported 89% complete-response rate applies across the patients covered by the update; the MRD-negative findings support the company’s statement that the rate could reach up to 98% when those cases are considered. The update concerns NEXICART-2, an investigational therapy for relapsed disease.
The result touches Immix Biopharma through the clinical-development value of NEXICART-2 and any later regulatory or commercial pathway for the therapy. The concrete mechanism is clinical: response durability, the significance of MRD negativity and subsequent study outcomes will determine how the interim data translate into a treatment profile.
The figures are interim rather than a completed clinical readout, and the announcement describes the 98% figure as potential. The sample cited here is 25 new patients, so the final interpretation depends on follow-up and later clinical evidence.
The next milestones are additional NEXICART-2 follow-up, a fuller study update and any regulatory interaction or filing tied to the program. Response durability, the persistence of MRD negativity and the eventual size of the evaluable dataset are the key facts that would settle the clinical read.
IMMX reported 21 complete responses among 25 new NEXICART-2 patients, with four more MRD-negative.
The interim efficacy signal could materially change how the market values NEXICART-2, but the decisive evidence is durability and confirmation beyond the 25-patient update. The clinical read is constructive, while the lack of a dated next milestone and the interim sample argue against a directional call here.
The read fails if later follow-up shows responses are not durable or if subsequent study results do not reproduce the interim signal.
CoverageSource: GlobeNewswire · Published here TUE, SEP 29 · 7:00 AM ET · 2 reports · 1 publisher in this record · latest listed: GlobeNewswire · TUE, SEP 29 · 12:12 PM ETHow this is decided →
Earlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
The reported 21 complete responses plus four MRD-negative patients gives NEXICART-2 a strong early efficacy profile and supports Immix’s potential best-in-class positioning.
The evidence is still interim and limited to 25 new patients, with the 98% figure explicitly framed as potential rather than an established final result.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →